About us
History
InfiCure Bio is a life science company, which started as a project at Umeå Biotech Incubator (UBI) in 2013. The project was initiated by Prof. Dan Holmberg and Dr. Sofia Mayans based on research conducted in the research group of Prof. Holmberg at the Universities of Umeå and Lund. The company, InfiCure Bio, was established in 2015 and the owners of the company are Dan Holmberg, Sofia Mayans and Åsa Larefalk.
Business Model
The base of the company is a unique preclinical fibrosis model together with the owners’ competence in the field of inflammation/fibrosis as well as in work with pre-clinical models.
Development of fibrosis in the model is spontaneous, seen in multiple organs (e.g. liver and kidney) and is preceded by chronic inflammation. This resembles many of the human condition that constitute important therapy segments eg chronic liver disease and chronic kidney disease.
The company’s preferred business model is to offer pharmaceutical companies to test their new anti-inflammatory/anti-fibrotic drugs in the unique model. The offer includes set-up, execution, analysis and reporting of results from the effect tests.
The company’s key strengths are:
- A unique preclinical fibrosis model
- Spontaneous development of fibrosis
- 100% reproducibility of the phenotype
- Early onset leading to shortened test protocols
- Competence in the field of inflammation/fibrosis
- Expertise in work with pre-clinical models
Management
Sofia Mayans, CEO
Sofia has a PhD in Medical Genetics and more than 10 years of experience from research in immunology, genetics and autoimmunity from Umeå University and Copenhagen University. She did her postdoc at La Jolla Institute for Allergy and Immunology in San Diego, USA. Sofia is currently CEO and member of the board of InfiCure Bio AB.
Dan Holmberg, Chairman of the Board
Dan has been a professor in Medical Genetics since 1999 at the Universities of Umeå, Copenhagen and Lund. He has more than 30 years of experience from research in immunology, autoimmune disease and inflammation. Co-founder of Symbicom AB, and co-founder and chairman of Famgen AB. Dan is currently chairman of the Board of InfiCure Bio AB.
Åsa Larefalk, Head of Product Development
Åsa has more than 25 years of research experience from Umeå Univeristy and the biotech industry. She has been part of the research team at Bionative AB, Symbicom AB and AstraZeneca AB. Åsa is currently member of the board of InfiCure Bio AB.